Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Sichuan Hebang Biotechnology Corporation Limited (603077.SS)
Chengdu, CN
Headquartered in Chengdu, China, Sichuan Hebang Biotechnology Corporation Limited, which originated in 2002, operates as a multifaceted enterprise. The company's core activities revolve around the development and distribution of products spanning agricultural, chemical, and advanced materials sectors. Its agricultural portfolio features biological pesticides, veterinary biological pharmaceuticals, and methionine. Within the chemical division, key offerings include sodium carbonate, ammonium chloride, soda ash, diglyphosate, glyphosate, and brine. Additionally, the firm is a producer of various glass types, such as standard, smart, specialized, and low-emissivity coated glass, alongside photovoltaic packaging and module components. Another significant business line involves the supply of oil and natural gas. The company rebranded to its present name in April 2021, having previously been known as SichuanHebang Biotechnology Co.,Ltd.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.77% | -6.46% | -16.89% | -16.04% | +12.33% | +8.85% | +40.57% | +2.93% | +25.51% | +48.19% | +136.54% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals: +4.0%-16.0% Q1'26: -19.6% (vs Q1'25)
-
EPS growth Chemicals: +11.7%-1,916.2% Q1'26: +1,708.3% (vs Q1'25)
-
FCF margin FCF growth · Chemicals: +41.7%-6.9% Q1'26: -16.5% (vs Q1'25)
-
EBIT margin Chemicals: +7.1%-2.0% Q1'26: +17.0% (vs Q1'25)
-
ROIC Chemicals: +3.4%-0.7% Q1'26: +3.9% (vs Q1'25)
-
Share dilution Chemicals: +0.0%-6.1% ★ Q1'26: -23.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals: 0.55×9.98× Q1'26: 9.61× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.86B
est: 4.66B (-38.6%)
|
3.46B
est: 4.66B (-25.7%)
|
4.74B
est: 3.28B (+44.5%)
|
6.01B
est: 4.46B (+34.8%)
|
5.97B
est: 5.10B (+17.1%)
|
5.26B
est: 5.85B (-10.1%)
|
9.99B
est: 10.86B (-8.1%)
|
13.04B
est: 13.95B (-6.5%)
|
8.82B
est: 9.84B (-10.3%)
|
8.55B
est: 11.47B (-25.5%)
|
7.18B
est: 12.92B (-44.4%)
|
| EBITDA |
620.40M
est: 1.35B (-54.0%)
|
811.95M
est: 1.35B (-39.8%)
|
1.14B
est: 948.04M (+20.5%)
|
1.18B
est: 1.29B (-8.2%)
|
1.28B
est: 1.47B (-13.2%)
|
1.17B
est: 1.69B (-31.1%)
|
4.28B
est: 3.14B (+36.3%)
|
5.40B
est: 4.03B (+33.9%)
|
2.41B
est: 2.84B (-15.3%)
|
924.25M
est: 3.09B (-70.1%)
|
873.07M
est: 3.48B (-74.9%)
|
| EBIT |
297.63M
est: 898.90M (-66.9%)
|
394.36M
est: 898.90M (-56.1%)
|
616.62M
est: 632.24M (-2.5%)
|
608.28M
est: 859.37M (-29.2%)
|
643.23M
est: 982.77M (-34.5%)
|
522.54M
est: 1.13B (-53.7%)
|
3.65B
est: 2.09B (+74.3%)
|
4.49B
est: 2.69B (+66.8%)
|
1.42B
est: 1.90B (-25.1%)
|
-50.43M
est: 1.94B (-102.6%)
|
-139.77M
est: 2.18B (-106.4%)
|
| Net Income |
239.87M
est: 309.24M (-22.4%)
|
317.81M
est: 309.24M (+2.8%)
|
517.54M
est: 347.89M (+48.8%)
|
363.09M
est: 579.82M (-37.4%)
|
516.85M
est: 657.13M (-21.3%)
|
40.94M
est: 927.70M (-95.6%)
|
3.02B
est: 2.85B (+6.0%)
|
3.81B
est: 4.21B (-9.6%)
|
1.28B
est: 1.28B (+0.6%)
|
31.46M
est: 1.20B (-97.4%)
|
-536.41M
est: 1.28B (-142.0%)
|
| SGA |
239.30M
est: 246.34M (-2.9%)
|
399.80M
est: 246.34M (+62.3%)
|
414.92M
est: 173.27M (+139.5%)
|
508.09M
est: 235.51M (+115.7%)
|
479.50M
est: 269.33M (+78.0%)
|
306.32M
est: 309.07M (-0.9%)
|
333.61M
est: 574.09M (-41.9%)
|
856.09M
est: 737.12M (+16.1%)
|
446.29M
est: 519.95M (-14.2%)
|
481.57M
est: 592.55M (-18.7%)
|
376.36M
est: 667.42M (-43.6%)
|
| EPS |
0.03
est: 0.04 (-12.6%)
|
0.04
est: 0.04 (+12.5%)
|
0.06
est: 0.04 (+46.7%)
|
0.04
est: 0.07 (-39.7%)
|
0.06
est: 0.08 (-22.7%)
|
0.00
est: 0.11 (-95.6%)
|
0.36
est: 0.34 (+6.8%)
|
0.44
est: 0.50 (-11.6%)
|
0.15
est: 0.15 (-1.7%)
|
0.00
est: 0.15 (-97.5%)
|
-0.07
est: 0.16 (-142.0%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-28 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-27 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-26 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-25 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-22 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-21 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-19 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-18 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-15 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-14 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-13 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-12 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-11 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-08 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF ASHS | 0.13% | 49.0K | 0.65% |
| 2 | Franklin FTSE China ETF FLCH | 0.01% | 25.2K | 0.19% |
| 3 | Franklin FTSE China UCITS ETF FLXC.L | 0.01% | 121.9K | 0.19% |
| 4 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 92.2K | 0.46% |
| 5 | Schwab Emerging Markets Equity ETF SCHE | 0.00% | 255.8K | 0.06% |
| 6 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 25.9K | 0.48% |
| 7 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 58.4K | 0.26% |
| 8 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 175.7K | 0.29% |
| 9 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 2.88M | 0.06% |
| 10 | FlexShares Morningstar Emerging Markets Factor Tilt Index Fund TLTE | 0.00% | 5.7K | 0.58% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jun Wang | Chief Financial Officer, Accounting Supervisor & Director | — | male |
| Siying Jiang | Secretary to the Board | — | female |
| Xiaoping Zeng | Chairman & GM | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 603077.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
